Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cochlear Limited (COH.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
222.75+2.79 (+1.27%)
At close: 4:10PM AEDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close219.96
Open222.87
Bid222.64 x 10000
Ask222.81 x 3400
Day's Range220.88 - 225.86
52 Week Range176.68 - 257.76
Volume105,643
Avg. Volume124,735
Market Cap14.651B
Beta (5Y Monthly)0.35
PE Ratio (TTM)44.85
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.80 (1.26%)
Ex-Dividend DateSep 23, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for COH.AX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    All
    News
    • PR Newswire

      Cochlear announces FDA approval and FDA clearance of first-of-its-kind Remote Care capabilities for Nucleus and Baha Systems

      Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval and clearance in the last month for its Cochlear™ Remote Assist solution in the Nucleus® and Baha® Systems. The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution are the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

    • PR Newswire

      'The Incredible Hulk' Lou Ferrigno hears with a cochlear implant

      During May's Better Hearing and Speech Month, Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, is pleased to celebrate Lou Ferrigno, 69, actor, fitness expert and retired bodybuilder, receiving a cochlear implant and addressing his hearing loss. Taking the step to treat his profound sensorineural hearing loss with a cochlear implant will aid Ferrigno's desire to remain fit and healthy as he ages.

    • PR Newswire

      New Cochlear CoPilot app to help adults improve hearing outcomes through skills training

      Adults with cochlear implants may be able to improve their listening and communications skills in daily life with the help of a new self-guided digital tool by Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions.

    Advertisement
    Advertisement